Clinical Trial

Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC

Name: Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC — clinical trial record (NCT06978829)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This prospective, single-arm, Phase II study aims to evaluate the efficacy, safety, and surgical conversion rate of Cetuximab combined with Tislelizumab and chemotherapy for unresectable LA HNSCC.

Trial Details

NCT Number	NCT06978829
Lead Sponsor	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Conditions	LA HNSCC
Enrollment	42 participants
Start Date	2025-03-01
Primary Completion	2027-03-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-05-18